FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953499734> ?p ?o ?g. }

• W2953499734 abstract "Background: Costimulation through 4-1BB (CD137) receptor has been targeted for cancer immunotherapy using agonistic antibodies, which have been shown to cause liver toxicity in preclinical and clinical settings. We hypothesized that this might not be a bona fide feature of 4-1BB signaling, but rather an antibody-mediated off-target effect. To test this hypothesis, we have generated a novel oligomeric form of the natural ligand, SA-4-1BBL, with robust costimulatory activity as a soluble protein. Pretreatment with SA-4-1BBL as a single agent protected mice against challenge with various tumor types, a feature that was not shared by an agonistic 4-1BB antibody. Study Design: C57BL/6 Mice were treated subcutaneously once or twice (two weeks apart) with various doses of SA-4-1BBL protein or an agonistic antibody (3H3) to 4-1BB, followed by challenge with various tumor cell lines subcutaneously into the left flank and monitored for tumor growth. For immunological studies, animals were treated with SA-4-1BBL twice, two weeks apart and then euthanized 7 days later to harvest various lymphoid tissues for immunophenotyping using flow cytometry. Antibodies against CD4 + T, CD8 + T, B, and NK cells were used in vivo to deplete individual cell types to assess their contribution towards the observed immune protection. Results: Pretreatment with SA-4-1BBL protected mice against 3 different tumor types, two lung cancer and one cervical cancer cell lines without detectable toxicity. The conferred protection against tumors was dose-dependent and evolved within two weeks of the first treatment. Importantly, the response was not tumor type-specific and lasted more than 8 weeks. In contrast to the protection conferred by SA-4-1BBL, pretreatment with the agonistic 4-1BB antibody had no impact on the tumor growth. Pretreatment with SA-4-1BBL expanded CD4 + CD44 + 4-1BB + T cells and NK cells producing IFN-γ. Our immune-cell depletion studies proved CD4 + T and NK cells to be indispensable for the observed anti-tumor effect. In marked contrast, depletion of CD8 + T cells or B cells had no significant impact on tumor growth. Also, in vivo blockade of IFN-γ negated SA-4-1BBL-conferred protection against tumor challenge. Conclusion: This study demonstrates unique and unexpected immunomodulatory features of SA-4-1BBL that bridge innate and adaptive immune responses with preventive efficacy against cancer. The tumor type-independent protection conferred by SA-4-1BBL is significant with important clinical implications for primary and secondary cancer prevention modalities. The safety profile of SA-4-1BBL and its cancer immunoprevention attributes are fundamental characteristics that are not shared by agonistic antibodies to the 4-1BB receptors. This highlights and emphasizes SA-4-1BBL’s potential for cancer immunoprevention and therapy. Funded in parts by NIH R41CA199956 award. Citation Format: Haval Shirwan, Hampartsoum B. Barsoumian, Lalit Batra, Pradeep Shrestha, William S. Bowen, Hong Zhao, Nejat K. Egilmez, Jorge G. Gomez-Gutierrez, Esma S. Yolcu. A novel form of 4-1BB agonist shows robust immune protection against various tumor types through CD4 + memory-like T and NK cell axis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4145." @default.
• W2953499734 created "2019-07-12" @default.
• W2953499734 creator A5000018437 @default.
• W2953499734 creator A5004759082 @default.
• W2953499734 creator A5026749521 @default.
• W2953499734 creator A5049976699 @default.
• W2953499734 creator A5050964019 @default.
• W2953499734 creator A5071785687 @default.
• W2953499734 creator A5077060710 @default.
• W2953499734 creator A5077647701 @default.
• W2953499734 creator A5091023729 @default.
• W2953499734 date "2019-07-01" @default.
• W2953499734 modified "2023-09-27" @default.
• W2953499734 title "Abstract 4145: A novel form of 4-1BB agonist shows robust immune protection against various tumor types through CD4+memory-like T and NK cell axis" @default.
• W2953499734 doi "https://doi.org/10.1158/1538-7445.sabcs18-4145" @default.
• W2953499734 hasPublicationYear "2019" @default.
• W2953499734 type Work @default.
• W2953499734 sameAs 2953499734 @default.
• W2953499734 citedByCount "0" @default.
• W2953499734 crossrefType "proceedings-article" @default.
• W2953499734 hasAuthorship W2953499734A5000018437 @default.
• W2953499734 hasAuthorship W2953499734A5004759082 @default.
• W2953499734 hasAuthorship W2953499734A5026749521 @default.
• W2953499734 hasAuthorship W2953499734A5049976699 @default.
• W2953499734 hasAuthorship W2953499734A5050964019 @default.
• W2953499734 hasAuthorship W2953499734A5071785687 @default.
• W2953499734 hasAuthorship W2953499734A5077060710 @default.
• W2953499734 hasAuthorship W2953499734A5077647701 @default.
• W2953499734 hasAuthorship W2953499734A5091023729 @default.
• W2953499734 hasConcept C118552586 @default.
• W2953499734 hasConcept C121608353 @default.
• W2953499734 hasConcept C159654299 @default.
• W2953499734 hasConcept C167672396 @default.
• W2953499734 hasConcept C187898756 @default.
• W2953499734 hasConcept C203014093 @default.
• W2953499734 hasConcept C2777701055 @default.
• W2953499734 hasConcept C2779448149 @default.
• W2953499734 hasConcept C2780249625 @default.
• W2953499734 hasConcept C2780674031 @default.
• W2953499734 hasConcept C502942594 @default.
• W2953499734 hasConcept C54355233 @default.
• W2953499734 hasConcept C71924100 @default.
• W2953499734 hasConcept C86803240 @default.
• W2953499734 hasConcept C8891405 @default.
• W2953499734 hasConceptScore W2953499734C118552586 @default.
• W2953499734 hasConceptScore W2953499734C121608353 @default.
• W2953499734 hasConceptScore W2953499734C159654299 @default.
• W2953499734 hasConceptScore W2953499734C167672396 @default.
• W2953499734 hasConceptScore W2953499734C187898756 @default.
• W2953499734 hasConceptScore W2953499734C203014093 @default.
• W2953499734 hasConceptScore W2953499734C2777701055 @default.
• W2953499734 hasConceptScore W2953499734C2779448149 @default.
• W2953499734 hasConceptScore W2953499734C2780249625 @default.
• W2953499734 hasConceptScore W2953499734C2780674031 @default.
• W2953499734 hasConceptScore W2953499734C502942594 @default.
• W2953499734 hasConceptScore W2953499734C54355233 @default.
• W2953499734 hasConceptScore W2953499734C71924100 @default.
• W2953499734 hasConceptScore W2953499734C86803240 @default.
• W2953499734 hasConceptScore W2953499734C8891405 @default.
• W2953499734 hasLocation W29534997341 @default.
• W2953499734 hasOpenAccess W2953499734 @default.
• W2953499734 hasPrimaryLocation W29534997341 @default.
• W2953499734 hasRelatedWork W1199770693 @default.
• W2953499734 hasRelatedWork W1980471102 @default.
• W2953499734 hasRelatedWork W1987649909 @default.
• W2953499734 hasRelatedWork W1990392443 @default.
• W2953499734 hasRelatedWork W1992291202 @default.
• W2953499734 hasRelatedWork W2011757360 @default.
• W2953499734 hasRelatedWork W2019105427 @default.
• W2953499734 hasRelatedWork W2030204783 @default.
• W2953499734 hasRelatedWork W2055069051 @default.
• W2953499734 hasRelatedWork W2085811812 @default.
• W2953499734 hasRelatedWork W2326276411 @default.
• W2953499734 hasRelatedWork W2384399723 @default.
• W2953499734 hasRelatedWork W2566317271 @default.
• W2953499734 hasRelatedWork W2887004316 @default.
• W2953499734 hasRelatedWork W2954612707 @default.
• W2953499734 hasRelatedWork W2955965100 @default.
• W2953499734 hasRelatedWork W3081641895 @default.
• W2953499734 hasRelatedWork W3082749686 @default.
• W2953499734 hasRelatedWork W3083110487 @default.
• W2953499734 hasRelatedWork W3105274064 @default.
• W2953499734 isParatext "false" @default.
• W2953499734 isRetracted "false" @default.
• W2953499734 magId "2953499734" @default.
• W2953499734 workType "article" @default.